Compare Revvity Inc (RVTY) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs TotalEnergies SE — how do they compare? Revvity Inc trades at $116.16 (market cap $12.91B), while TotalEnergies SE trades at $87.8 (market cap $196.06B). The key difference: TotalEnergies SE is far larger — about 15.2× Revvity Inc's market cap, and TotalEnergies SE pays the higher dividend (4.82%). Which is the better fit depends on your goals.
| RVTY | TTE | |
|---|---|---|
Market Cap | $12.91B | $196.06B |
Sector | Technology | Energy |
52-Week High | $117.75 | $93.60 |
52-Week Low | $82.26 | $57.39 |
Enterprise Value | $15.23B | $227.06B |
Dividend Yield | 0.24% | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
TotalEnergies (TTE) trades at $87.49, down 0.53% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $94.00. The company reported mixed recent earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, while revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent strategic moves include acquiring Shell's European onshore renewables business and developing the Cronos gas field in Cyprus, signaling a shift toward integrated energy.
TTE presents a value opportunity with a low P/E of 11.01 and strong cash flow, but faces headwinds from declining revenue and regulatory climate litigation. The stock's upside is supported by analyst bullishness and dividend payments, yet investors must weigh energy transition execution risks against its current attractive valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
